Renal involvement in SLE, known as Lupus Nephritis, is one of the most serious manifestations of SLE. It develops in about 30% of patients of SLE and mostly afflicts females. Survival of the patients has improved significantly over the last 40 years with the currently available drugs.
InTRoduCTIon
Systemic Lupus Erythomatosus (SLE) is defined and diagnosed by the clinical features in conjunction with the presence of one or more autoantibodies directed against nuclear antigens or phospholipids. The most commonly used diagnostic criteria are those developed by the American college of Rheumatology 1 Approximately 25% to 60% of unselected patients with SLE have renal involvement as assessed by urinalysis or impairment of renal function but often the mild. As with SLE in general, the spectrum of lupus nephritis (LN) is wide, encompassing the acute nephritic syndrome, nephritic syndrome, acute or chronic renal failure, and isolated abnormalities of the urinary sediment.
However, proteinuria is the most constant feature, being present in almost every patient with clinical lupus nephritis 3 .
Although microscopic haematuria is common, it rarely occurs in isolation. 
EpIdEmIology
Prevalence between 25 and 250 per 100,000 persons, depending on racial and geographic background. It is more prevalent in Asians and blacks. It is predominant in females, male:female, ratio is 1: 9. It is common in the age group of 20-40 years. 
pAThophySIology
In recent years, evidence has emerged that the process of apoptosis is disturbed in SLE. Alteration in apoptosis can lead to the persistence of antoreactive T and B cells, because apoptosis is the major mechanism for the elimination of antoreactive cells.
Nucleosomes are the basic structures of chromatin. Recently it has become evident that the nucleosome is the driving auto antigen in SLE. In murine and human lupus, T cells specific for nucleosomes have been identified. These T cells not only drive the formation of nucleosomes specific autoantibodies but also the formation of anti DNA and antihistone antibodies. These antinucleosome and anti DNA antibodies after complex formation with the nucleosome, can localize in the glomerular besement membrane (GBM) 6 . These excites the glomerular inflammation. Furthermore, it has recently become evident that autoantibodies expressed on cells also play an important role in pathogenesis 7 .
Recent data have shown the dendritic cells may have a central role in SLE pathogenesis directing the immune response against the antigens.
There are accumulating data from human studies and mouse lupus models consistent with an important role for dysregulated interferon (IFN) alpha production in lupus pathogenesis. DNAanti DNA immune complexes in the sera of the patients with SLE possibly induce IFN-alpha production by plasma cytoid dendritic cells, the major cell type in the body specially dedicated to INFalpha production 8 .
An additional mechanism is observed in SLE patients with antiphospholipid antibody syndrome (APLA). APLA nephropathy is characterized by interstitial, tubular or glomerular injury due to obstruction of large, medium sized or small vessels. It has recently been shown that APLA nephropathy is an independent risk factor, over and above LN, that contributes to an elevated prevalence of hypertension, elevated seram creatinine, increased interstitial fibrosis and chronic renal insufficiency 5 .
REnAl pAThology
Most patients with LN have immune complex mediated glomerulonephritis (GN) charactoeized by positive glomerular immunofluorescence (IF) for IgG and usually IgM, IgA, C3 and C1q.
Additionally, other nonglomerular lesion can be seen in LN, including tubulointerstitial nephritis and vascular lesions such as immunoglobulin vascular deposits arteriosclerosis, vasculitis, arteriolar thrombi or overt thrombotic microangiopathy. Arteriolar thrombi and overt microangiopathy often occur in presence of APLA.
Renal biopsy in patients with suspected active LN is essential for confirming the diagnosis and for guiding management as prognosis and treatment options depend on the pathological class of GN 9 .
ClASSIfICATIon
The classification of SLE nephritis has evolved over the past 40 years as more lesions were identified and defined. The first WHO classification of SLE was made at New York in 1974 and published in 1978 10 . 1982 modification of WHO classification is described below. • Urinary microalbumin / creatinine ratio.
• Blood anti ds DNA • Serum C 3 , C 4 , ANA, Antiphospholipid antibodies, Urea, Creatinine, APTT
• Renal biopsy
For class I and II treatment is hydroxychloroquin orally 200mg or 400 mg daily. This is well tolerated, however, biannual fundoscopic examination by an ophthalmologist is essential for signs of toxicity.
Patients presenting with class III or class IV disease are managed aggressively. Blood pressure is managed with sodium restriction, vassodilators, diuretics and beta blockers. Angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers are avoided in the setting of acutely changing renal function because these drugs may occasionally cause a temporary decrease in renal function. Hyperkalaemia and hyponatraemia needs correction and occasionally, acute dialysis is indicated.
Diagnosis of Lupus Nephritis
Treatment independent of class The Euro-Lupus Nephritis Trial found that treatment response at 6 months in terms of reduced creatinine and proteinuria, was be best predictor of long term renal outcome. Proteinuria, however, can take a long time to reach baseline levels and normalization of urine is not the same as loss of histological disease activity. Response to treatment thus is not the same as disease remission. Aim of treatment thus is to reduce the risk of end stage renal disease (ESRD) and death, control of proteinuria and prevention of flares. Patients who have nephritic flares are almost seven times as likely to progress to ESRD compared to those who do not 17 .
NeW THeRAPIeS fOR LuPuS NePHRITIS (LN) IN pRogRESS
New therapies for LN have to be at least as effective as and less toxic than existing therapies, with improved understanding of the immunopathogenesis of SLE, novel immunological targeted therapies are being described and delivered. These include both B and T cell directed therapies, anticytokine therapies, complement directed treatments as well as immunoblative chemotherapy and 
lupuS nEphRITIS In pREgnAnCy
The effect of the gestation in women with SLE who have renal involvement is difficult to evaluate, in part because of the unpredictable course of disease regardless of pregnancy. In about 10% gestation appears to cause permanent renal damage.
Placental transmission of maternal autoantibodies is associated with an increased frequency of spontaneous abortion in these women and cause a neonatal lupus syndrome. Pregnant women with circulating antiphospholipid antibodies can manifest a rare form of rapid renal failure postpartum, associated with glomerular thrombi. Therefore women with SLE should be screamd for antiphospholipid antibodies early in gestation.
A flare of LN may difficult to distinguish from preeclampsia when a women with history of lupus develops worsening renal function, proteinuria and hypertension. Elevation in liver enzymes and new In spite of treatment kidneys may fail dialysis and Renal Transplantation (RT) will then need to be considered onset severe hypertension is more consistent with preeclampsia.
A flare of nephritis in the third trimester appears to trigger "superimposed preeclampsia" and improvement in BP and proteinuria occurs only after delivery. However, in the presence of abnormal serologic testing, it is often reasonable to treat worsening proteinuria and azotemia with increased prednisolone in the hope that it will improve, particularly if the fetus is immature 19 .
